Comorbidities of chronic obstructive pulmonary disease

Current Opinion in Pulmonary Medicine

Volumn 17, Issue SUPPL. 1, 2011, Pages

  Corsonello, Andrea ^a   Antonelli Incalzi, Raffaele ^b,c   Pistelli, Riccardo ^d   Pedone, Claudio ^b,e   Bustacchini, Silvia ^a   Lattanzio, Fabrizia ^a  

^a INRCA   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c San Raffaele Foundation   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e Alberto Sordi Foundation   (Italy)

Author keywords

comorbidity; COPD; elderly; guidelines

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; STEROID; TIOTROPIUM BROMIDE;

ANEMIA; AORTA ANEURYSM; ARTICLE; ATHEROSCLEROSIS; BLADDER CANCER; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE DEFECT; COMORBIDITY; CONGESTIVE HEART FAILURE; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; DYSPHAGIA; GLAUCOMA; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; LEG THROMBOSIS; LUNG CANCER; LUNG EMBOLISM; MUSCLE ATROPHY; OSTEOPOROSIS; PROSTATE HYPERTROPHY; PULMONARY HYPERTENSION; SLEEP APNEA SYNDROME; STEROID THERAPY;

ADRENERGIC BETA-ANTAGONISTS; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; FEMALE; HUMANS; INFLAMMATION; KIDNEY DISEASES; LUNG NEOPLASMS; MALE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SLEEP APNEA, OBSTRUCTIVE;

EID: 84855367507     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000410744.75216.d0     Document Type: Article

References (56)

1. Marengoni A, Rizzuto D, Wang HX et al. Patterns of chronic multimorbidity in the elderly population. J Am Geriatr Soc 2009; 57:225-230.
2. Menzin J, Boulanger L, Marton J et al. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. Respir Med 2008; 102:1248-1256.
3. Pauwels RA, Buist AS, Calverley PM et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163:1256-1276. (Pubitemid 32378468)
4. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2010. http://www.goldcopd.org/. [Accessed October 10, 2011]
5. Antonelli Incalzi R, Fuso L, De Rosa M et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997; 10:2794-2800. (Pubitemid 28052790)
6. Fuso L, Incalzi RA, Pistelli R et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995; 98:272-277.
7. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005; 128:2005-2011. (Pubitemid 41507534)
8. Soriano JB, Visick GT, Muellerova H et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005; 128:2099-2107. (Pubitemid 41507547)
9. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59:574-580. (Pubitemid 38901515)
10. Gan WQ, Man SF, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 2005; 127:558-564. (Pubitemid 40229317)
11. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007; 370:797-799. (Pubitemid 47320803)
12. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33:1165-1185.
13. Barabasi AL. Network medicine: from obesity to the 'diseasome'. N Engl J Med 2007; 357:404-407.
14. Bolton CE, Schumacher W, Cockcroft JR et al. The CRP genotype, serum levels and lung function in men: the Caerphilly Prospective Study. Clin Sci (Lond) 2011; 120:347-355.
15. Dahl M, Vestbo J, Zacho J et al. C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach. Thorax 2011; 66:197-204.
16. Sunyer J, Pistelli R, Plana E et al. Systemic inflammation, genetic susceptibility and lung function. Eur Respir J 2008; 32:92-97.
17. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22 (4 Suppl A):6A-13A. (Pubitemid 23285789)
18. Lederle FA, Nelson DB, Joseph AM. Smokers' relative risk for aortic aneurysm compared with other smoking-related diseases: a systematic review. J Vasc Surg 2003; 38:329-334. (Pubitemid 41123258)
19. van den Borst B, Gosker HR, Zeegers MP, Schols AM. Pulmonary function in diabetes: a metaanalysis. Chest 2010; 138:393-406.
20. Fimognari FL, Pasqualetti P, Moro L et al. The association between metabolic syndrome and restrictive ventilatory dysfunction in older persons. J Gerontol A Biol Sci Med Sci 2007; 62:760-765. (Pubitemid 350143608)
21. Incalzi RA, Corsonello A, Pedone C et al. Chronic renal failure: a neglected comorbidity of COPD. Chest 2010; 137:831-837.
22. Casanova C, de Torres JP, Navarro J et al. Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182:1004-1010.
23. Tishler PV, Larkin EK, Schluchter MD, Redline S. Incidence of sleep-disordered breathing in an urban adult population: the relative importance of risk factors in the development of sleep-disordered breathing. JAMA 2003; 289:2230-2237. (Pubitemid 37430191)
24. Incalzi RA, Gemma A, Marra C et al. Verbal memory impairment in COPD: its mechanisms and clinical relevance. Chest 1997; 112:1506-1513. (Pubitemid 28007755)
25. Leech JA, Dulberg C, Kellie S et al. Relationship of lung function to severity of osteoporosis in women. Am Rev Respir Dis 1990; 141:68-71. (Pubitemid 20023384)
26. de Luise C, Brimacombe M, Pedersen L, Sorensen HT. Chronic obstructive pulmonary disease and mortality following hip fracture: a population-based cohort study. Eur J Epidemiol 2008; 23:115-122.
27. Bon J, Fuhrman CR, Weissfeld JL et al. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med 2011; 183:885-890.
28. Gross RD, Atwood CW Jr, Ross SB et al. The coordination of breathing and swallowing in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 179:559-565.
29. Stephenson A, Seitz D, Bell CM et al. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study. Arch Intern Med 2011; 171:914-920.
30. Hanania NA, Mullerova H, Locantore NW et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med 2011; 183:604-611.
31. Coventry PA. Does pulmonary rehabilitation reduce anxiety and depression in chronic obstructive pulmonary disease? Curr Opin Pulm Med 2009; 15:143-149.
32. Ries AL, Bauldoff GS, Carlin BW et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest 2007; 131 (5 Suppl):4S-42S. (Pubitemid 46744215)
33. Nuti R, Siviero P, Maggi S et al. Vertebral fractures in patients with chronic obstructive pulmonary disease: the EOLO Study. Osteoporos Int 2009; 20:989-998.
34. Ionescu AA, Schoon E. Osteoporosis in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003; 46:64s-75s. (Pubitemid 37351738)
35. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003; 21:892-905. (Pubitemid 36592303)
36. Incalzi RA, Fuso L, De Rosa M et al. Electrocardiographic signs of chronic cor pulmonale: a negative prognostic finding in chronic obstructive pulmonary disease. Circulation 1999; 99:1600-1605. (Pubitemid 29152928)
37. Boyd CM, Darer J, Boult C et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294:716-724. (Pubitemid 41159291)
38. Pedone C, Lapane KL. Generalizability of guidelines and physicians' adherence. Case study on the Sixth Joint National Committee's guidelines on hypertension. BMC Public Health 2003; 3:24.
39. Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 2007; 297:1233-1240. (Pubitemid 46465731)
40. Holmes HM. Rational prescribing for patients with a reduced life expectancy. Clin Pharmacol Ther 2009; 85:103-107.
41. Berry CE, Wise RA. Mortality in COPD: causes, risk factors, and prevention. COPD 2010; 7:375-382.
42. Hawkins NM, Petrie MC, Macdonald MR et al. Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Betaagonists. J Am Coll Cardiol 2011; 57:2127-2138.
43. Kazani S, Israel E. Treatment with beta blockers in people with COPD. BMJ 2011; 342:d2655.
44. Rutten FH, Zuithoff NP, Hak E et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170:880-887.
45. Short PM, Lipworth SI, Elder DH et al. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011; 342:d2549.
46. Bartziokas K, Papaioannou AI, Minas M et al. Statins and outcome after hospitalization for COPD exacerbation: a prospective study. Pulm Pharmacol Ther 2011; 24:625-631.
47. Di Marco F, Guazzi M, Vicenzi M et al. Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: a pilot study. Pulm Pharmacol Ther 2010; 23:159-164.
48. Mortensen EM, Copeland LA, Pugh MJ et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10:45.
49. Young RP, Hopkins R, Eaton TE. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev 2009; 18:222-232.
50. Young RP, Hopkins R, Eaton TE. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad Med J 2009; 85:414-421.
51. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107:1514-1519. (Pubitemid 36378490)
52. Celli B, Decramer M, Leimer I et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137:20-30.
53. Corsonello A, Pedone C, Corica F et al. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med 2005; 165:790-795. (Pubitemid 40569433)
54. Yang IA, Fong KM, Sim EH et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007: CD002991.
55. Ferguson GT, Calverley PM, Anderson JA et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 2009; 136:1456-1465.
56. Martinez FJ, Donohue JF, Rennard SI. The future of chronic obstructive pulmonary disease treatment: difficulties of and barriers to drug development. Lancet 2011; 378:1027-1037.